Cargando…
Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival
Two first analyses of our clinical trial on TIL as adjuvant therapy for melanoma were published in 2002 and 2007. We present here an update of the clinical results after a 17-year median followup. In this trial, disease-free patients were randomly assigned to receive either TIL/IL-2 or IL-2. The rel...
Autores principales: | Khammari, Amir, Knol, Anne-Chantal, Nguyen, Jean-Michel, Bossard, Céline, Denis, Marc-Guillaume, Pandolfino, Marie-Christine, Quéreux, Gaëlle, Bercegeay, Sylvain, Dréno, Brigitte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987883/ https://www.ncbi.nlm.nih.gov/pubmed/24741578 http://dx.doi.org/10.1155/2014/186212 |
Ejemplares similares
-
Tissue Biomarkers in Melanoma Patients Treated with TIL
por: Knol, Anne-Chantal, et al.
Publicado: (2012) -
Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients
por: Saint-Jean, Mélanie, et al.
Publicado: (2018) -
Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy
por: Herbreteau, Guillaume, et al.
Publicado: (2018) -
Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study
por: Herbreteau, Guillaume, et al.
Publicado: (2021) -
Value of large scale expansion of tumor infiltrating lymphocytes in a compartmentalised gas-permeable bag: interests for adoptive immunotherapy
por: Zuliani, Thomas, et al.
Publicado: (2011)